Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

BioNTech confirmed the successful completion of its public tender offer for CureVac on December 18, 2025, with the acceptance period closing at 0:01 Eastern Time. The all-stock transaction was valued ...

The publicly traded chapter for CureVac has closed. The biotechnology firm's shares have ceased trading and have been formally delisted from the Nasdaq exchange, marking the final step in its full ...

A major regulatory milestone was achieved in November 2025 when Germany’s Federal Cartel Office (Bundeskartellamt) granted clearance for the takeover. BioNTech had initially announced the exchange ...

Official closure of the transaction occurred on January 6, 2026. BioNTech is now the sole owner of CureVac's entire business operations and developmental pipeline. Trading in the Tübingen biotech's ...

The era of CureVac as an independent, publicly traded company has drawn to a close. This significant milestone follows the completion of its acquisition by riva ...

The independent chapter for one of Germany's most prominent biotech names has officially closed. CureVac, the Tübingen-based ...

BioNTech SE (F:22UAy) (NASDAQ:BNTX) has been downgraded to “market perform” from “outperform” by Leerink Partners after a ...

The downgrade follows a 24% rise in BioNTech’s shares to $113 from December lows of $92, a move that outpaced the 4% gain in the S&P Biotechnology Select Industry Index over the same period. Leerink ...

BioNTech SE is methodically advancing its transition from a COVID-19 vaccine specialist to a fully-fledged oncology company, achieving significant regulatory and operational milestones in early 2026.

BioNTech SE (NASDAQ:BNTX) ranks among the best high growth European stocks to buy. On January 16, Goldman Sachs upgraded ...